Literature DB >> 17561685

[History of chronic fatigue syndrome].

Nobuya Hashimoto1.   

Abstract

Chronic fatigue syndrome (CFS) is not a new disease. Similar morbidities have been known as different names since past several centuries. For example, neurasthenia, epidemic neuromyasthenia, myalgic encephalomyelitis, Akureyri disease, Royal Free disease, chronic EBV disease, post-viral fatigue syndrome etc. Much of the recent interest in CFS was generated by incidence of infection-like outbreak at Lake Tahoe in Nevada. The Center for Disease Control (USA) realized that correlation was poor between those patients who had virologic evidence of EBV infection and those who had the symptoms of chronic fatigue. This is a review of the history of CFS. (1) Historical perspectives in chronic fatigue cases in past old period, (2) Post-viral infectious fatigue and chronic fatigue (myalgic encephalomyelitis), (3) Recent trend of CFS studies and its clinical similar situation. Finally, I would like to state that we intend to draw up a new diagnostic guideline for CFS in Japan.

Entities:  

Mesh:

Year:  2007        PMID: 17561685

Source DB:  PubMed          Journal:  Nihon Rinsho        ISSN: 0047-1852


  3 in total

1.  Increased risk of chronic fatigue syndrome following herpes zoster: a population-based study.

Authors:  S-Y Tsai; T-Y Yang; H-J Chen; C-S Chen; W-M Lin; W-C Shen; C-N Kuo; C-H Kao
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-04-09       Impact factor: 3.267

Review 2.  Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A Comprehensive Review.

Authors:  Mateo Cortes Rivera; Claudio Mastronardi; Claudia T Silva-Aldana; Mauricio Arcos-Burgos; Brett A Lidbury
Journal:  Diagnostics (Basel)       Date:  2019-08-07

Review 3.  A Molecular Neurobiological Approach to Understanding the Aetiology of Chronic Fatigue Syndrome (Myalgic Encephalomyelitis or Systemic Exertion Intolerance Disease) with Treatment Implications.

Authors:  Jean A Monro; Basant K Puri
Journal:  Mol Neurobiol       Date:  2018-02-06       Impact factor: 5.590

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.